Full-Time
Business Development Associate
Posted on 1/9/2023
Iterative Health
51-200 employees
AI-driven solutions for gastrointestinal healthcare
Junior
Cambridge, MA, USA + 1 more
More locations: New York, NY, USA
- Minimum 2 years of client-facing experience in a strategic, commercial role (e.g., management consulting, business development, corporate strategy, investment banking, partnerships, etc.)
- Experience navigating healthcare stakeholders (especially biopharma and/or providers) and a baseline understanding of the healthcare ecosystem in the US
- Strong ability to navigate ambiguity by developing logical frameworks, conducting secondary research, independently driving workstreams, and clearly communicating data-driven results to convince others
- Enthusiastic about collaborating with and learning from others
- Able to work from our Cambridge Headquarters, where we have a hybrid working environment
- Design and conduct research to select and prioritize new commercial growth levers and present recommendations to senior leaders
- Work closely with a variety of cross-functional teams to guide partnership approaches for the business
- Manage strategic partnerships to ensure the success of ongoing projects and build new avenues for growth and collaboration
- Develop new contracts and support contract negotiations with business partners
- Exposure to project work in gastroenterology (especially colorectal cancer and/or IBD)
- Exposure to project work in medical devices
- Experience conducting primary research
- Basic understanding of artificial intelligence and how it can be applied to healthcare
- Experience working in / for a startup
Iterative Health focuses on improving gastrointestinal (GI) care through the use of artificial intelligence (AI) and machine learning (ML). Their main product, SKOUT®, is an FDA-cleared device designed to help doctors detect adenomas, which are precursors to colorectal cancer. This device works alongside physician judgment to enhance the accuracy of diagnoses. In addition to SKOUT®, Iterative Health provides services that optimize clinical trials by using AI-enabled documentation technology, which improves patient care and ensures high-quality reporting across different healthcare institutions. This technology aims to make advanced care more accessible, especially to underserved populations. Unlike many competitors, Iterative Health combines AI technology with a strong focus on colorectal cancer prevention and clinical trial efficiency. The company's goal is to deliver top-tier GI care and improve health outcomes for patients worldwide.
Company Size
51-200
Company Stage
Series B
Total Funding
$182.1M
Headquarters
Boston, Massachusetts
Founded
2017
Simplify's Take
What believers are saying
- AI-driven predictive analytics enable personalized treatment plans in gastroenterology.
- Partnerships with Gastro Health and One GI® expand clinical research capabilities.
- $150M Series B funding accelerates AI innovations in gastroenterology care.
What critics are saying
- Competition from tech giants in AI medical imaging threatens market share.
- Rapid expansion may strain resources, affecting service quality.
- Reliance on AI exposes potential biases, risking inaccurate diagnoses and liabilities.
What makes Iterative Health unique
- Iterative Health uses AI to enhance GI care, focusing on colorectal cancer.
- SKOUT® device aids in adenoma detection, improving diagnostic accuracy in GI treatments.
- AI-enabled documentation optimizes clinical trials, enhancing research quality and patient care.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Vision/Dental/ Medical Insurance
Life/Disability Insurance
Parental Leave
Stock Options
Flexible Work Hours
Unlimited Paid Time Off
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 1%Machine Vision & HealthTogether with LLMs (large language models) like ChatGPT, machine vision is one of the most important recent developments in AI. The various methods used to achieve it, such as neural networks and deep learning, are now allowing computers to truly see their environment.One application of this idea is letting computers take over humans' tasks like driving or giving robots full autonomy in the real world instead of staying confined to factory floors.It is one one of the large drivers of machine vision adoption, a quickly growing market expected to reach $9.2B by 2029.But another equally important task is judging our health. Many medical diagnoses rely on doctors' visual assessments. This includes direct examination and expert-level analysis of radiography, scanners, and other medical images.In most cases, these visual inspections are somewhat subjective. A doctor will need many years of experience to become truly confident in his assessment. And until now, the complexity of each patient’s body being slightly different made it too complex for automatized measurement.This is finally changing, and many companies are now exploring deploying AI machine vision to create superior analyses of medical images.Direct Visual ExaminationWe recently explored the case of using AI to detect better than human doctor ear infections in our article “AI Poised to Become Invaluable Medical Diagnosis Tool”This can be expanded to many other pathologies; for example, Google's AI imaging can be used to diagnose 26 different skin diseases (80% of cases seen in primary care), detect diabetic retinopathy , or even predict the risk of developing diabetic retinopathy in the future .More surprisingly, AI also appears to be able to detect health issues from visual inspections that humans could not use; for example, detecting anemia (normally requiring a blood test) from a look at the eye’s retina
Iterative Scopes Raises $150M to accelerate development of its core algorithmic innovations designed to transform gastroenterology care for patients
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Iterative Health, a pioneer in precision-medicine technologies for gastroenterology, announced today that it has partnered with Gastro Health, a national leading medical group specializing in digestive and liver health, to bring its AI Recruitment (AIR) technology to Gastro Health’s practices. This strategic partnership will lay the groundwork for future collaborations by using AIR to aid in the recruitment of patients for clinical trials in inflammatory bowel disease (IBD) and expanding Gastro Health’s clinical research capabilities.Gastro Health is one of the largest national medical groups specializing in digestive and liver health and has a presence in seven states – Florida, Alabama, Washington, Virginia, Ohio, Maryland, and Massachusetts – with over 380 physicians and 150 locations consisting of medical offices, infusion centers, imaging services, and a specialty pharmacy. Gastro Health owns and operates endoscopy centers as well as pathology and anesthesia services. Iterative Health is a pioneer in the application of advanced artificial intelligence (AI) tools in gastroenterology. To date, the company has raised $195M in funding and is rapidly growing in pursuit of its mission to use computer vision-based technology to reduce disparities in healthcare. Iterative Health has partnered with multiple clinical research sites and continues to expand its impact and reach through this relationship with Gastro Health.“ Our shared mission with Iterative Health to democratize access to the highest quality GI care has opened the door for us to utilize AIR in our practices,” said Joseph Garcia, CEO of Gastro Health
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Iterative Scopes, a pioneer in precision-medicine technologies for gastroenterology, announced today that it has partnered with One GI®, a gastroenterology management services organization (MSO), to bring its AI Recruitment (AIR) technology to One GI’s clinical research. Initially, One GI® will use AIR at Gastro One, one of One GI’s clinical research sites in Memphis, Tennessee, with plans to expand to additional research sites within the One GI® network. The implementation of AIR will aid in the recruitment of patients for clinical trials focused on inflammatory bowel disease (IBD). Both One GI® and Iterative Scopes are fast-growing innovators in the gastroenterology space. One GI® is a unique, rapidly expanding MSO that brings together community-based practices, including Gastro One, a network of six practices across Tennessee. The MSO currently has 40 sites within its network across Tennessee, Mississippi, Kentucky, Ohio, and Indiana. Iterative Scopes is a pioneer in the application of powerful, proprietary artificial intelligence tools to the practice of gastroenterology and drug development
Annual list recognizes innovators and leaders in life-sciences who positively impact the industry at large. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Iterative Scopes, a pioneer in precision-medicine technologies for gastroenterology, announced today that Jonathan Ng, MBBS, the company’s founder and CEO, has been named to the PharmaVoice 100 — an annual list that recognizes the most inspiring people in the life-sciences industry